Baker Bros. Advisors Adds $25M in Enliven Therapeutics, Inc. ($ELVN)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Baker Bros. Advisors increased its position in Enliven Therapeutics, Inc. ($ELVN) by 233.52% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 905,191 shares of Enliven Therapeutics, Inc. after buying 633,785 shares during the quarter. Baker Bros. Advisors's holdings in Enliven Therapeutics, Inc. were worth $36.22 million as of its most recent filing.
Enliven Therapeutics, Inc. Stock Down 30.9%
Shares of Enliven Therapeutics, Inc. ($ELVN) traded around $40.01 on Saturday, down 30.9% for the day.
Enliven Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Get Enliven Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ELVN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.